The objective of this study is to describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Brazil.
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Demographical characteristics of patients who have received palbociclib combination treatments in line with locally approved indications
Timeframe: 30 days after prescribed palbociclib + partner therapy until completion of this study in 2022.
Adjuvant treatments received for subset of patients previously diagnosed with non-metastatic breast cancer who progressed to locally advanced (stage IIIB/C) or metastatic (stage IV) breast cancer.
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe treatments received in the advanced/metastatic setting before palbociclib combination use
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe treatments received in the advanced/metastatic setting after palbociclib combination use
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe dosing associated with palbociclib use in clinical practice
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe dose changes associated with palbociclib use in clinical practice
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe interruptions associated with palbociclib use in clinical practice
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe delays associated with palbociclib use in clinical practice
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe discontinuations associated with palbociclib use in clinical practice
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe supportive therapies received by patients while receiving palbociclib combination treatments
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Proportion of patients who are progression free following clinical outcomes in overall population and defined subgroups for patients who had a potential follow-up of 6 months after palbociclib combination treatment initiation
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Real world Objective response rate (ORR) following clinical outcomes in overall population and defined subgroups for patients who had a potential follow-up of 6 months after palbociclib combination treatment initiation
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Proportion of patients alive following clinical outcomes in overall population and defined subgroups for patients who had a potential follow-up of 6 months after palbociclib combination treatment initiation
Timeframe: 30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.